戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 penicillin; 4 patients were not treated with pentoxifylline.
2 the effect of treatment with prednisolone or pentoxifylline.
3  a group that received both prednisolone and pentoxifylline.
4 eceiving prednisolone; 546 were treated with pentoxifylline.
5 ich was less frequent in the group receiving pentoxifylline.
6 chloride] but not by the TNF-alpha inhibitor pentoxifylline.
7 (1501-S) and the oxidized side chain analog, pentoxifylline.
8 -controlled study of adjunctive therapy with pentoxifylline (1800 mg/day) as a timed-release formulat
9  or a combination of anakinra (14 days) plus pentoxifylline (28 days) plus zinc (COMB; 180 days).
10  mg of prednisolone once a day and 400 mg of pentoxifylline 3 times a day (n=133) for 28 days, or 40
11                 Relative to enprofylline 2b, pentoxifylline 35 was equipotent and 1-propylxanthine 3
12 nty-nine patients were randomized to receive pentoxifylline 400 mg p.o. t.i.d. or matching placebo fo
13 treatment with prednisolone (40 mg daily) or pentoxifylline (400 mg 3 times each day) in patients wit
14                                    Saline or pentoxifylline (5 or 20 mg/kg im) was administered daily
15                                              Pentoxifylline (50 mg/kg body weight) or an equivalent v
16 2 and were receiving continuous therapy with pentoxifylline 800 mg 3 times a day and ciprofloxacin 50
17 apsing fever were infused intravenously with pentoxifylline 90 min before intramuscular injection of
18 estigated on pulmonary arterial responses to pentoxifylline, acetylcholine, and isoproterenol during
19                 Low-dose (but not high-dose) pentoxifylline administration reduced production of some
20                                              Pentoxifylline administration, however, significantly in
21 o determine whether or not administration of pentoxifylline after trauma-hemorrhagic shock has any sa
22  mortality; low quality evidence showed that pentoxifylline also decreased short-term mortality (RR,
23  failure; in animal models its blockade with pentoxifylline ameliorates AP.
24 lline-matched placebo, a group that received pentoxifylline and a prednisolone-matched placebo, or a
25                     Vasodilator responses to pentoxifylline and acetylcholine were not significantly
26                  In patients with severe AH, pentoxifylline and corticosteroids (alone and in combina
27   Based on direct and network meta-analysis, pentoxifylline and obeticholic acid improve fibrosis, an
28 ltration rate or creatinine was seen between pentoxifylline and placebo groups at any interval.
29 h alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisol
30                             The abilities of pentoxifylline and recombinant interleukin-10 (rIL-10) t
31                              Combinations of pentoxifylline and rIL-10 led to additive or synergistic
32 icantly reduced the vasodilator responses to pentoxifylline and to acetylcholine, whereas NG-L-nitro-
33  Inhibitors of TNF-alpha production (GM6001, pentoxifylline) and TNF-alpha Ab's reduced serum and kid
34             Clinical trials with cladibrine, pentoxifylline, and budesonide have failed to demonstrat
35  the perfusion-modifying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate
36 harmacologic interventions (corticosteroids, pentoxifylline, and N-acetylcysteine [NAC], alone or in
37 oderate-quality evidence supports that TZDs, pentoxifylline, and obeticholic acid decrease lobular in
38 h as progestational agents, cyproheptadines, pentoxifylline, and thalidomide may work by down-regulat
39 n ATF3/4-dependent manner, whereas caffeine, pentoxifylline, and theophylline do not.
40 hat unlike other xanthines such as caffeine, pentoxifylline, and theophylline, they do not deregulate
41                             Prednisolone and pentoxifylline are both recommended for the treatment of
42                            Administration of pentoxifylline at 5 mg/kg/day also down regulated the pr
43            Intraperitoneal administration of pentoxifylline before LPS inhibited TNF-alpha synthesis
44                                              Pentoxifylline consistently inhibited the accumulation o
45                           Patients receiving pentoxifylline demonstrated improved AROM, PROM, and mus
46 induced G2 arrest by treatment with the drug pentoxifylline did not abrogate apoptosis.
47                                              Pentoxifylline did not attenuate this process and had no
48                                              Pentoxifylline did not improve survival in patients with
49                                              Pentoxifylline did not prevent clearance of the B. recur
50 , montelukast, danazol, H(2)-antihistamines, pentoxifylline, doxepin, and tranexamic acid are not eff
51  present data also suggest that responses to pentoxifylline during increased tone conditions may, in
52 injection of a TNFalpha synthesis inhibitor, pentoxifylline, during skin tumor promotion completely p
53 ately incubated in the sampling syringe with pentoxifylline, erythro-9-(2-hydroxy-3-nonyl) adenine, a
54                               Treatment with pentoxifylline failed to prevent fever, increase in puls
55                                          The pentoxifylline group had fewer intensive care unit admis
56 odestly between baseline and 6 months in the pentoxifylline group, but not in the placebo group, and
57 13% (35 of 260 patients) in the prednisolone-pentoxifylline group.
58                           Patients receiving pentoxifylline had no adverse effects.
59                         These data show that pentoxifylline has significant vasodilator activity in t
60 odulators, and more recently thalidomide and pentoxifylline have been used to treat BD with varying d
61 s fed the high-protein liquid diet and given pentoxifylline in a dose of 5 mg/kg/day demonstrated imp
62  72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.
63 early reports of renal protective effects of pentoxifylline in bone marrow transplant recipients prom
64                              The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested
65                                              Pentoxifylline inhibits expression of TNF-alpha and HIV.
66                             After 8 weeks of pentoxifylline intervention, 20 of 23 patients with impa
67 rsus-host disease prophylaxis with steroids, pentoxifylline, intravenous immunoglobulin, and total bo
68                              Prednisolone or pentoxifylline is recommended for severe alcoholic hepat
69  one of four groups: a group that received a pentoxifylline-matched placebo and a prednisolone-matche
70 bo, a group that received prednisolone and a pentoxifylline-matched placebo, a group that received pe
71                   Emerging data suggest that pentoxifylline may also be beneficial in improving serum
72 ilable in patients with type 1 HRS, although pentoxifylline may be effective to treat HRS in patients
73                     A series of analogues of pentoxifylline metabolites were prepared in the purine,
74  of malignant cells with the c-Rel inhibitor pentoxifylline not only reduced c-Rel nuclear translocat
75 tions (prednisone plus creatine inhibited by pentoxifylline) of combinatorial therapies taken by some
76 , and a study showing the effect of systemic pentoxifylline on ocular blood flow and diabetes.
77 ected alveolar macrophages were treated with pentoxifylline or anti-TNF-alpha antibody.
78 a was attenuated by administration of either pentoxifylline or anti-TNF-alpha serum, and liver injury
79 rticosteroids (alone and in combination with pentoxifylline or NAC) can reduce short-term mortality.
80 e randomized within 72 hours of diagnosis to pentoxifylline or placebo.
81 paring vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or pl
82 nimals given the high dose (20 mg/kg/day) of pentoxifylline (p< .05).
83                                              Pentoxifylline (PF) has been used in a wide variety of c
84 nical use of the methyl xanthine derivative, pentoxifylline (PF), for the treatment of T cell-depende
85 acebo group, 19% (50 of 258 patients) in the pentoxifylline-placebo group, and 13% (35 of 260 patient
86                   A combination of anakinra, pentoxifylline plus zinc provides similar survival benef
87  postoperative days (POD) 1, 3, 5, and 7; or pentoxifylline pre-reperfusion and at POD 1 to 5.
88 s, 6-month survival was not different in the pentoxifylline-prednisolone and placebo-prednisolone gro
89 onths was not significantly different in the pentoxifylline-prednisolone and the placebo-prednisolone
90  block of JHR was attempted by administering pentoxifylline prior to antibiotic treatment.
91 rats with anticytokine agents, etanercept or pentoxifylline, produced very similar results.
92                                     Although pentoxifylline produces various beneficial effects follo
93                                              Pentoxifylline promotes gut ketogenesis following trauma
94                                              Pentoxifylline (PTF) inhibits synthesis of some cytokine
95 ctive, randomized trial to determine whether pentoxifylline (PTF), which reduces albuminuria, in addi
96 ategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably expressed
97                                              Pentoxifylline (PTX) directly decreases lung endothelial
98                                              Pentoxifylline (PTX) improved the histological features
99             Previous studies have shown that pentoxifylline (PTX) in combination with alpha-tocophero
100  of this study was to compare the effects of pentoxifylline (PTX) versus placebo on the histological
101       We hypothesized that administration of pentoxifylline (PTX), a phosphodiesterase inhibitor know
102 ntiangiogenic potential of an existing drug, pentoxifylline (PTX), which inhibits PKC-dependent activ
103                                              Pentoxifylline resulted in decreased plasma HIV RNA and
104 oderate-quality evidence supports the use of pentoxifylline (RR, 0.26; 95% CrI: 0.05-1.00) and obetic
105 val [CrI], 0.39-0.73) or in combination with pentoxifylline (RR, 0.53; 95% CrI, 0.36-0.78) or NAC (RR
106                        New agents, including pentoxifylline, thalidomide, and infliximab have proved
107             There was no association between pentoxifylline therapy and the risk of serious infection
108 of this study was to evaluate the ability of pentoxifylline to alter gut cytokine production in a rat
109 10 appeared to interfere with the ability of pentoxifylline to block iNOS accumulation.
110                 The addition of NAC, but not pentoxifylline, to corticosteroids may be superior to co
111                                        Thus, pentoxifylline treatment of patients with relapsing feve
112 leukin 6, or interleukin-8 was observed with pentoxifylline treatment.
113 was also inhibited by both dexamethasone and pentoxifylline, two pharmacological agents with potentia
114     The odds ratio for 28-day mortality with pentoxifylline was 1.07 (95% confidence interval [CI], 0
115 medications such as S-adenosylmethionine and pentoxifylline will need further confirmation by additio
116                                              Pentoxifylline within 72 hours of pSAP is safe; a larger

 
Page Top